ARMO BioSciences Garners $50,000,000 Series C Round

  • Feed Type
  • Date
    2/10/2016
  • Company Name
    ARMO BioSciences
  • Mailing Address
    575 Chesapeake Drive Redwood City, CA 94063 USA
  • Company Description
    ARMO BioSciences is a biopharmaceutical company that develops immunotherapies for the treatment of Cancer, Cardiovascular Diseases, Fibrosis and Inflammation. ARMO’s lead product AM0010, is a PEGylated form of recombinant human Interleukin-10 (PEG-rHuIL-10).
  • Website
    http://www.armobio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $50,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    ARMO intends to use the proceeds from the financing to support the clinical development of its lead product candidate, AM0010 for the treatment of advanced solid tumors, and its pipeline of immunotherapies, including cytokines and an anti-Programmed Cell Death Protein (anti-PD-1) monoclonal antibody checkpoint inhibitor.
  • M&A Terms
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    OrbiMed
  • Venture Investor
    DAG Ventures
  • Venture Investor
    NanoDimension
  • Venture Investor
    HBM BioCapital
  • Venture Investor
    GV
  • Venture Investor
    Celgene
  • Venture Investor
    Industrial Investors
  • Venture Investor
    Clough Capital Partners

Trending on Xconomy